QUEST - BIH CENTER FOR TRANSFORMING BIOMEDICAL RESEARCH

QUALITY | ETHICS | OPEN SCIENCE | TRANSLATION

Action plan towards Open Science Open Science Workshop Berlin 22.9.2017







Let's think about cognitive bias

New agreement to

tackle pharmaceutical

pollution a 164

The human brain's habit of finding what it wants to find is a key problem for research. Establishing robust methods to avoid such bias will make results more reproducible.

ver since I first learned about confirmation bias I've been see-Some researchers already do this well, so one relatively simple strategy

Reproducibility: Seek out stronger science

Monya Baker

Nature 537, 703-704

nature IS BECOMING A CRUCIAL PART OF LAB LIFE.

Fewer numbers,

better science

Scientific quality is hard to define, and numbers are easy to look at. But bibliometrics are warping

science - encouraging quantity over quality.

Leaders at two research institutions describe

how they do things differently.

Acknowledging and Overcoming Nonrep in Basic and Preclinical Research



NATURE | NEW S

Missing mice: gaps in data plague animal resea

Reports of hundreds of biomedical experiments lack essential information.

Hide results to seek the truth More fields should, like particle physics, adopt blind analysis

to thwart bias, urge Robert MacCoun and Saul Perlmutter

Believe it or not: how much a rely on published data on po

Low statistical power in biomedical science: a review of three human research domains



Scientific method: Statistical errors

P values, the 'gold standard' of statistical validity, are not as reliab assume.

Confidence in preclinical research

or decades, model organisms have provided an important reductionist approach for understanding

making strides in their efforts to understand and for the complexity of the microbiome in rodent m Perrin S (2014) Nature 407:423-

DUE DILIGENCE, OVERDUE

Dilumeted

Results of rigorous animal tests by the Amyotrophic Lateral Sclerosis Therapy Development Institute (ALS T are less promising than those published. All these compounds have disappointed in human testing.

DATA SHARING An open mind on open data

The move to make scientific findings transparent can be a major boon to research, but it can be tricky to embrace the change.

Power failure: why small sample size undermines the reliability of

neuroscience

haring C Button 1.2 John D A L

Repetitive flaws

Strict guidelines to improve the reproducib: of experiments are a welcome move.

rom next week, scientists who submit grant applications to National Institutes of Health (NIH) will be asked to take more care. As part of an increasing drive to boost the rel of research, the NIH will require applicants to explain the sci premise behind their proposals and defend the quality of their mental designs. They must also account for biological variab example, by including both male and female mice in planned s and describe how they will authenticate experimental materia as cell lines and antibodies.

These demands are timely, sensible and, if researchers hav following the advice of their scientific societies, will sound fa Over the past year, a string of organizations have published the statements and guidelines to boost the reproducibility of research.



for example, ca practices. The of everything f is not studied preclinical cancer research infrastructure Society has de And the Amer to create comi

works, and fur



Reality check on reproducibility

A survey of Nat results. Resean NATURE | NEWS

Raise standards for

C. Glenn Begley and Lee M. Ellis propose how methods, publications and

incentives must change if patients are to benefit.



n inspire



"85% of health research is wasted."

Metrics for ethics

Focus on perceived working conditions could help graduate

et up

aring

schools to train responsible researchers.

ROYAL SOCIETY

OPEN SCIENCE

rsos.royalsocietypublishing.org

Check for

Challenges in academic biomedicine (selection)



Methodology

- Concerns about reliability and reproducibility.
- Weaknesses in planning, conducting, analysing, and reporting.
- Underutilized sharing, evaluation, and synthesis of high quality evidence.
- Nonpublication of results.
- Conflicts of interest (...among others)

Ethics and policy

- Focus on robust evidence of clinical promise as well as safety to hold the first tests of drugs in humans to a higher standard.
- Despair of patients means they often fail to consider the major risks intrinsic to early clinical trials of novel modalities such as stem cell interventions and gene therapy. (...among others)

Research governance

• Economic pressures and current reward structures can antagonize methodological robustness and rigor, as well as stimulate overinterpretation of results.



QUEST Mission Statement



.... to increase the value of biomedical research at BIH and beyond.



QUEST Approach

- **Open Science:** improve the accessibility and transparency of BIH research and its results through Open access and Open data.
- **Quality assurance:** promote compliance of preclinical and clinical research with standards and guidelines on design, conduct, analysis and reporting.
- Education: develop and implement training and teaching resources on experimental and study design, methods to reduce bias, new modes of publishing, open science, etc.
- Meta-Research: identify opportunities for improving research practice and obtain evidence for the impact of its activities through 'research on research'.

- **Rewards and incentives:** develop, implement, and assess the impact of novel indicators incentives and metrics to improve the current funding, reward and career system in academic research.
- **Research for and with the public:** foster public outreach and public involvement in BIH research (Citizen science / Participatory health research).
- Bioethics of translation: implement innovative, scientifically informed policies and training modules for research quality and human protections.
- **Think tank:** act as advisors to stakeholders in biomedicine from funders to politics.

QUEST Team





Dr. Stephanie Ohlraun Administrative Head: Overall coordination and budgets



Lisa Liebenau Open Science Officer: open access representative BIH/Charité, publication officer



Dr. Nico Riedel Data Scientist: Data and text mining, social network- and bibliometric analyses



Dr. Miriam Kip Indicators & Incentives officer ('Good evaluation practice')



Dr. Ulf Toelch Education, Training – Quality of research



NN IT administrator: digital research infrastructures, repositories, electronic lab notebook

QUEST Research Groups





Prof. Dr. Ulrich Dirnagl, BIH-Chair and QUEST Founding Director Research Group 'Transforming biomedical research'



BIH-Professor (NN) Research Group 'Bioethics of translation'



Junior group leader (NN)

Research Group 'Improving value of preclinical research through meta-research'

BIH Professorship 'Bioethics of Translation'





Jonathan Kimmelmann (call)

Associate Professor in the Biomedical Ethics Unit, Social Studies of Medicine, McGill University, Montreal



Daniel Strech (loco secundo)

Institute for History, Ethics and Philosophy of Medicine, Hannover Medical School



QUEST Scientific Advisory Panel



Gerd Antes

Cochrane Deutschland, Freiburg, Germany



Alastair Buchan University of Oxford, Medical School und Medical Sciences Division, Oxford, UK



Katherine Button University of Bath, Department of Psychology, Bath, UK



John P.A. Ioannidis Stanford University, School of Medicine, School of Humanities and Sciences, Meta-Research Innovation Center, Stanford, USA



Emily Sena University of Edinburgh, Centre for Clinical Brain Sciences, Edinburgh, UK



Examples of ongoing projects



Open science policy - FAIR use of data Counseling / Education / Training









QUEST OA FUND

Berlin

Projektantrag

Freie Universität

Einrichtung eines Publikationsfonds für die Charité – Universitätsmedizin Berlin und Verstetigung der Finanzierung von Open-Access-Publikationen

Förderlinie: Wissenschaftliche Literatur- und Informationssysteme Förderprogramm: Open Access Publizieren Teil 8 Beschreibung des Vorhabens

Antragsteller:


Univ.-Prof. Dr. Peter-André Alt, Präsident Freie Universität Berlin, Kaiserswerther Str. 16-18, 14195 Berlin

Prof. Dr.-Ing. Dr. Sabine Kunst, Präsidentin, Humboldt-Universität zu Berlin, Unter den Linden 6, 10099 Berlin

Ansprechpartner:

Prof. Dr. Axel Radlach Pries, Dekan Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin





BIH OPEN ACCESS PUBLICATION FUND

To promote the publication in open access journals, the QUEST – BIH Center for Transforming Biomedical Research offers the payment of Open Access fees for a total of up to 15 publications. The applications are processed according to the order in which they are received.

The costs for your Open Access publication can be paid by the QUEST Center if the following formal criteria are met:

- 1. The publication has already been accepted by the publisher.
- The first, last or corresponding author of the publication is professor or "Privatdozent" at the Charité, leading researcher at the MDC or published with the <u>BIH affiliation</u>.
- 3. The journal in which you have published is listed in the <u>DOAJ Directory of Open Access</u> Journals and is not a so-called hybrid journal.
- Your article is licensed under a <u>Creative Commons license</u> (preferably CC by) and can be used without restrictions.
- 5. The publisher's invoice is addressed to the BIH.

Please apply the payment of your Open Access fee here: BIH Portal

Questions can be addressed to: <u>openscience@bihealth.de</u>

TD_1.2 Show and P....m... ^ (a) PR_2.08 Holes (1).mkv ^

Unsure whether you are eligible to apply?

Just send us your open access paper and we will check the fulfillment of the criteria for you.

Contact

Lisa Liebenau

Referentin für Open Science Open-Access-Beauftragte BIH und Charité

openscience@bihealth.de

Alle anzeigen 🛛 🗙

Initiatives (continued...)



Preregister your preclinical studies challenge - Increase the credibility of your results and get early credit for your ideas!

BERLIN

harité & May Delbrück Center

The QUEST Center supports the preregistration of planned preclinical studies. Preregistration increases the credibility of results, the conclusions based on them, and secures the originality of ideas and hypotheses before experiments have been performed.

QUEST is offering **15** awards of **1,000** € to first/last/corresponding BIH, MDC or Charité authors of preclinical research papers containing preregistered (basic or translational, not clinical) studies.

The QUEST 1,000 € NULL results and Replication study Award

Publish your NULL results - Fight the negative publication bias!

Publish your Replication Study - Fight the replication crises!

The QUEST Center supports the publication of results which do not support the initial hypothesis, so called NULL results, sometimes unfairly labelled as 'negative studies'. We also want to promote the publication of studies with the explicit attempt to replicate own results or the results of others.

QUEST is offering **15 awards of 1,000 €** each to first/last/corresponding BIH, MDC or Charité authors of research papers in which the main result is a NULL or 'negative', or in which the replication of own results or the results of others is attempted. Basic, translational as well as clinical studies are eligible.

The QUEST 1,000 € Open Data Award

Make your data FAIR - Findable, Accessible, Interoperable, and Re-usable!

The QUEST Center strives to make relevant research data findable, accessible, interoperable and re-useable ('FAIR').

QUEST is offering **15** awards of **1,000** € each to first/last/corresponding BIH, MDC or Charité authors of research papers which have unconditionally shared their original data by citing them in the references of the paper via the persistent identifier of an open repository containing the annotated data. Basic, translational as well as clinical studies are eligible.

Develop and deploy structured quality management, e.g. roll out Electronic Laboratory Notebook



FICCOResearch E1000Research 2016, 5:2 Last updated: 25 JUL 2016 CrossMark C

F1000Research 2016, 5:2 (doi: 10.12688/f1000research.7628.1)





Develop and deploy structured quality management, e.g. LabCritical Incidence Reporting



PLOS BIOLOGY


COMMUNITY PAGE

A Laboratory Critical Incident and Error Reporting System for Experimental Biomedicine

 $\label{eq:Urich Dirnagl} Ulrich \ Dirnagl^{1,2,3,4,5\,*}, Ingo \ Przesdzing^1, Claudia \ Kurreck^1, Sebastian \ Major^1$

PLOS Biology | DOI:10.1371/journal.pbio.2000705 December 1, 2016





Develop and implement novel (& more efficient) study designs



PERSPECTIVE

Increasing efficiency of preclinical research by group sequential designs

Konrad Neumann¹[®], Ulrike Grittner^{1,2®}*, Sophie K. Piper^{1,2,3}, Andre Rex^{2,4}, Oscar Florez-Vargas⁵, George Karystianis⁶, Alice Schneider^{1,2}, Ian Wellwood^{2,7}, Bob Siegerink^{2,8}, John P. A. Ioannidis⁹, Jonathan Kimmelman¹⁰, Ulrich Dirnagl^{2,3,4,8,11,12}

> Stage 3 Stage Stage 2 Frequentist: Reject H_0 if $P < \alpha_3$ Baves: State d≠0 if 0 is not in the 96.8% credible interval of effect size d n₃=36 n₁=12 $n_{2}=24$ Interim analysis 1 Interim analysis 2 Frequentist: Terminate Frequentist: Terminate and reject H_0 if $P < \alpha_2$ and reject H_0 if $P < \alpha_1$ Bayes: Terminate if 0 is Bayes: Terminate if 0 is not in the 99.8% credible not in the 96.8% credible interval of effect size d interval of effect size d





Final analysis



PLOS Biol (2017) 15:e2001307

IMI Project - Data quality in preclinical research development

European Quality In Preclinical Data (EQIPD)

11 industry partners (Coordinated by T.Steckler, Janssen)



elbrück Center



- 18 applicants (coordinated by M.Macleod/E.Sena U Edinburgh)
 - 10 Universities (Germany, Netherlands, Switzerland, UK)
 - 6 SMEs
 - 1 scientific society
 - 1 PMO




PREMIER - Predictiveness and Robustness through Modular Improvement of Experimental Research



Structured quality assurance *from and for* academic preclinical biomedicine - Establishment and proof of concept








Develop and deploy good institutional practice (incl. novel incentives and rewards)





Institutions must do their part for reproducibility

Tie funding to verified good institutional practice, and robust science will shoot up the agenda, say C. Glenn Begley, Alastair M. Buchan and Ulrich Dirnagl.

3 SEPTEMBER 2015 | VOL 525 | NATURE | 25

International Survey on Organizational Research Climate und Research Practice





International Survey on Organizational Research Climate und Research Practice




Part 4 Items regarding publication practices

| <u>1.4a</u> | How committed are researchers in your immediate research environment to apply open access in their publication practice? | Not at All Somewhat Moderately Very Completely No Basis for Judging |
|-------------|---|--|
| <u>I.4b</u> | How committed are researchers in your immediate research environment to apply open data principles when publishing research results? | (1) Not at All (2) Somewhat (3) Moderately (4) Very (5) Completely (9) No Basis for Judging |
| <u>1.4c</u> | How committed are the senior administrators at your institution (Charité / MDC) (e.g., deans, executive board, scientific directorate) to apply open access in their publication practice? | (1) Not at All (2) Somewhat (3) Moderately (4) Very (5) Completely (9) No Basis for Judging |
| <u>l.4d</u> | How committed are the senior administrators at your university institution (Charité / MDC) (e.g., deans, chancellors, executive board, scientific directorate vice presidents) to apply open data principles when publishing research results? | Not at All Somewhat Moderately Very Completely No Basis for Judging |

Novel indicators for performance oriented INS funding




until now:




Novel indicators for performance oriented IN funding



from 2018:






| Topics |
|--|
| |
| Main Focus: Science * |
| e.g. Apoptosis + |
| Main Focus: Clinic |
| e.g. Clinical Psychotherapy |
| |
| Please describe in short what you believe is your scientific contribution in your scientific field. |
| [scientific contribution] |
| Remaining characters: 1000 |
| What do you consider to be the 5 most important papers you have published? Please briefly justify this selection and mention your respective contribution. How were the work accepted in the scientific field, what impact did they have on the advancement of knowledge or the clinical practice (therapies, guidelines)? * |
| [Pubmed-ID] OR [DOI] |
| [Description of first publication] |
| |
| The Charite attaches great importance to transparent, replicable research and supports the objectives of Open Science (Open Access, Open Data). This includes the registration of studies in registries (clinicaltrials.gov, DRKS, etc.), the preregistration of studies, and the publication of negative and zero results. How have you been pursuing these goals so far and what are your plans for the future? |
| |
| |
| Remaining characters: 1000 |
| Charité is interested in team science and collaborations. Please describe in short most important collaboration projects within recent five years. * |
| e.g. Karolinska Inst. |
| [Description] - + |
| Please describe in short your interactions with relevant actors in biomedicine, e.g. industry, patient care, policy panel, etc. |
| |
| |
| |
| Remaining characters: 1000 |
| |
| relevant patents [patent number] |
| [Description] - + |
| |


Novel perspective on publication records





Tracking (and safeguarding) the publication of clinical trials








Medizinische Hochschule Hannover





Outreach to the public and participatory research (MIDATA) - pilot with BELOVE





Policy: E.g. counseling FDA on QM in 'unregulated' biomedical research






Quality Management for Academic Labs: Burden or Boon?

Ulrich Dirnagl, Ph.D.

Date: May 31, 2017, 10-11:30AM FDA White Oak Campus Building 2, Room 2051 and Webinar



Lost in the Maze? Navigating Evidence and IN Ethics in Translational Neurosciences







The Herrenhausen Conference on February 14-16, 2018 in Hannover focuses on major scientific and ethical challenges of novel neurological interventions and how they can be overcome. Participants will explore how critically needed trials of new treatment modalities can be launched safely and conducted ethically.

herrenhäuser KONFERENZEN http://www.volkswagenstiftung.de/hktranslationalneuroscience

FEBRUARY 14 - 16, 2018 / HANOVER, GERMANY LOST IN THE MAZE? NAVIGATING EVIDENCE AND ETHICS IN TRANSLATIONAL NEUROSCIENCE HERRENHAUSEN CONFERENCE

ORGANI7ED BY

Prof. Dr. Ulrich Dirnagl, Charité Berlin and Berlin Institute of Health Prof. Mark Yarborough, UC Davis

FUNDED BY **VolkswagenStiftung** MORE INFORMATION www.volkswagenstiftung.de/hktranslationalneuroscience



Alison Abbott (Nature Publishing Group/USA), Enrica Alteri (European Medicines Agency/UK), Christopher Baum (Hannover Medical Bredenoord School/Germany). Julie Belluz(Vox.com/USA), Annelien (Utrecht University/The Netherlands). Virginie **Bros-**Facer (Eurordis/France), Dominique Brossard (University of Wisconsin-Madison/USA), Leena Bruckner-Tuderman (Albert-Ludwigs-University of Freiburg and Deutsche Forschungsgemeinschaft/Germany), Alex Capron (University of Southern California/USA), Timothy Caulfield (University of Alberta/Canada), Iain Chalmers (James Lind Initiative/UK), Isabelle Clavier (Sanofi/France), Katherine Cowan (James Lind Alliance/UK), Ulrich Dirnagl (Charité Berlin and Berlin Institute of Health/Germany), Jodi Halpern (University of California Berkeley /USA), Henrike Hartmann (Volkswagen Foundation/Germany), Insoo Hyun (Case Western Reserve University/USA), John Ioannidis (Stanford University/USA), Katie Jackson (Help 4 HD International), Nanette Joyce (University of California Davis/USA), Scott Kim(National Institutes of Health/USA), Jonathan Kimmelman (McGill University/Canada), Paul Knoepfler (University of California Davis/USA), Wilhelm Krull (Volkswagen Foundation/Germany), Malcom Macleod (University of Edinburgh/UK), Frank Miedema (University Medical Center Utrecht/The Netherlands), Jeffrey Mogil (McGill University/Canada), Ubaka Ogbogu (University of Alberta/Canada), Sarah Perrault (University of California Davis/USA), Laurent Pradier (Sanofi/France), Axel Radlach Pries (Charité Berlin/Germany), Bernard Ravina (Voyager Therapeutics/USA), Emily Sena (University of Edinburgh/UK), Shai Silberberg (National Institutes of Health/USA), Daniel Strech (Hannover Medical School/Germany), Thomas Streckler (Janssen Pharmaceutics/Belgium), Vicki Wheelock (University of California Davis/USA), Hanno Würbel (University of Bern/Switzerland), Mark Yarborough (University of California Davis/USA) and others.....

The OPENING of the QUEST Center for Transforming BiomedicalResearchNovember 16/17, 2017, Berlin

Program – November 16, 2017

- Venue: Charité Campus Mitte, Charitéplatz 1, 10117 Berlin Address on Campus: Hörsaalruine, Virchowweg 17
- 6:30-7:00 pm Registration
- 7:00-7:15 pm OPENING REMARKS by Martin LOHSE (Berlin Institute of Health, Max Delbrück Center for Molecular Medicine) and Axel Radlach PRIES (Berlin Institute of Health, Charité - Universitätsmedizin Berlin)
- 7:15-8:15 pm
 KEYNOTE LECTURE by David MOHER

 The quest for better behavior in science
 Ottawa Hospital Research Institute; School of Epidemiology and Public Health, University of Ottawa, Canada
- 8:15-10:00 pm CHEESE, WINE & MUSIC



Registration and program: <u>http://bit.ly/questopening</u>

Program – November 17, 2017

- Venue: Festsaal der Humboldt Graduate School, Luisenstraße 56, 10115 Berlin
- 8:45-9:15 am Registration & Coffee
- 9:15-9:30 am WELCOME REMARKS by Ulrich DIRNAGL (Berlin Institute of Health, Charité - Universitätsmedizin Berlin)
- 9:30-11:00 am TALKS by Ivan ORANSKY, Ernst HAFEN and Trish GROVES

Ivan ORANSKY

Retractions, post-publication peer review, and fraud: scientific publishing's Wild West

Ernst HAFEN

Genome meets iPhone – citizen-controlled use of personal data for research Department of Biology, Institute of Molecular Systems Biology, ETH Zürich, Switzerland

Trish GROVES

Open Science: why it's much more than simply data sharing (and why that's not simple) The BMJ, UK

11:00-11:30 am Coffee break

11:30 am-1:00 pm TALKS by Londa SCHIEBINGER, Daniel STRECH and Frank MIEDEMA

Londa SCHIEBINGER

Gendered innovations in health and medicine *History Department, Stanford University, USA*

Daniel STRECH

Effective and efficient bioethics of translation! How to? Institute for History, Ethics and Philosophy of Medicine, Hannover Medical School, Germany

Frank MIEDEMA

New incentives and rewards for better science: the dean's perspective University Medical Center Utrecht, Netherlands



Registration and program: <u>http://bit.ly/questopening</u>